Maryam Lustberg
Yale University · Yale University Comprehensive Cancer Center · Ohio State University Comprehensive Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Maryam Lustberg as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:04 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07689864 · Unified Network for Integrated Fluid Collection at YaleYale University · recruiting · Molecular Residual Disease, Cancer · principal investigator
- Ph2NCT07426822 · Rash & Diarrhea Prophylaxis With CapivasertibMaryam Lustberg · recruiting · Metastatic HR+/HER2- Breast Cancer · principal investigator
- Ph2NCT06917313 · FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine TherapyYale University · recruiting · Breast Cancer Early Stage Breast Cancer (Stage 1-3) · principal investigator
- Ph1NCT05989347 · Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant TherapyYale University · recruiting · Breast Cancer, Hyperinsulinism, HER2-negative Breast Cancer · principal investigator
- Ph3NCT05379153 · Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize TrialAlliance for Clinical Trials in Oncology · recruiting · Vaginal Atrophy, Breast Carcinoma · study chair
- N/ANCT03039140 · Cardiac Rehabilitation Program in Improving Cardiorespiratory Fitness in Stage 0-III Breast Cancer SurvivorsOhio State University Comprehensive Cancer Center · completed · Cancer Survivor, Stage 0 Breast Cancer, Stage IA Breast Cancer · principal investigator
- N/ANCT01987726 · Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid TumorsOhio State University Comprehensive Cancer Center · completed · Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Rectal Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Cancer Survivorship Training InstituteR25CA314973 · NCI · YALE UNIVERSITY · fiscal years 2026 · $316,200 awarded in 2026Same name and institution; not confirmed by an ID
- Dance-based Avenues to Advance Nonpharmacologic treatment of Chemotherapy Effects (DAANCE): a multicenter trialR01AG084676 · NIA · OHIO STATE UNIVERSITY · fiscal years 2024 to 2026 · $857,282 awarded in 2026Same name and institution; not confirmed by an ID
- Prevention of paclitaxel-induced peripheral neuropathy with nilotinibR01CA238946 · NCI · OHIO STATE UNIVERSITY · fiscal years 2019 to 2023 · $569,420 awarded in 2023Same name and institution; not confirmed by an ID
- Novel Interventions for Chemotherapy-Induced NeuropathyR21AG068831 · NIA · OHIO STATE UNIVERSITY · fiscal years 2021 to 2022 · $81,709 awarded in 2022Same name and institution; not confirmed by an ID
- Effect of n-3 fatty acids and sugars on chemotherapy-induced cognitive deficitsR01CA189947 · NCI · OHIO STATE UNIVERSITY · fiscal years 2015 to 2018 · $438,106 awarded in 2018Same name and institution; not confirmed by an ID
- Gait and Balance Changes in Chemotherapy Induced Peripheral NeuropathyR03CA182165 · NCI · OHIO STATE UNIVERSITY · fiscal years 2014 to 2015 · $77,000 awarded in 2015Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Alliance NCORP Research BaseUG1CA189823 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis, Olwen Hahn, ELECTRA D. PASKETT · fiscal years 2014 to 2026Named on NCT05379153
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:04 UTC. The ranking covers the 200 most relevant of 41 PubMed records, and a shared surname and initials can bring in a namesake. All 41 on PubMed
- Tolerability and feasibility of at-home remotely supervised transcranial direct current stimulation (RS-tDCS): Single-center evidence from 6,779 sessions.Brain Stimul · 202284 citationsRCR 8.9
- Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors.Clin Cancer Res · 201959 citationsRCR 2.0
- Pilot randomized controlled trial of a symptom cluster intervention in advanced cancer.Psychooncology · 201942 citationsRCR 2.4
- Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer.Cancer Chemother Pharmacol · 201338 citationsRCR 1.0
- Pilot study of fractional CO2 laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors.Maturitas · 202137 citationsRCR 3.6
- 36 citationsRCR 0.8
- Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain.Breast Cancer Res Treat · 201833 citationsRCR 1.8
- Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer.Clin Breast Cancer · 201430 citationsRCR 1.0
- A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer.Invest New Drugs · 202030 citationsRCR 1.3
- Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.Clin Breast Cancer · 201125 citationsRCR 0.7